Received Jan 8, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | EY57A | — |
Patient was administered the second dose of Havrix about a month after the first dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 43-year-old male patient who received HAV (Havrix 1440) (batch number EY57A, expiry date 03-OCT-2026) for prophylaxis. Previously administered products included Havrix 1440 (Received 1st dose of Havrix 1440 vaccine on 17-JUN-2025). On 22-JUL-2025, the patient received the 2nd dose of Havrix 1440. On 22-JUL-2025, an unknown time after receiving Havrix 1440, the patient experienced drug dose administration interval too short (Verbatim: Patient was administered the second dose of Havrix about a month after the first dose). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 06-JAN-2026